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Abstract
The conduct of high-quality nutrition research requires the selection of appropriate markers as outcomes, for example as indicators of food or
nutrient intake, nutritional status, health status or disease risk. Such selection requires detailed knowledge of the markers, and consideration of
the factors that may inﬂuence their measurement, other than the effects of nutritional change. A framework to guide selection of markers
within nutrition research studies would be a valuable tool for researchers. A multidisciplinary Expert Group set out to test criteria designed to
aid the evaluation of candidate markers for their usefulness in nutrition research and subsequently to develop a scoring system for markers.
The proposed criteria were tested using thirteen markers selected from a broad range of nutrition research ﬁelds. The result of this testing was
a modiﬁed list of criteria and a template for evaluating a potential marker against the criteria. Subsequently, a semi-quantitative system for
scoring a marker and an associated template were developed. This system will enable the evaluation and comparison of different candidate
markers within the same ﬁeld of nutrition research in order to identify their relative usefulness. The ranking criteria of proven, strong, medium
or low are likely to vary according to research setting, research ﬁeld and the type of tool used to assess the marker and therefore the
considerations for scoring need to be determined in a setting-, ﬁeld- and tool-speciﬁc manner. A database of such markers, their interpretation
and range of possible values would be valuable to nutrition researchers.
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Introduction
A biomarker has been deﬁned as ‘a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses to
an intervention’(1). Thus, biomarkers are measurements that reﬂect
biological processes and they can be various sorts of data, such as
physiological measurements; analyses of tissues, blood or other
body ﬂuids; metabolic data; genetic data; or measurements from
bio-images. In recent years new technologies have enabled the
simultaneous measurement of genetic sequences, messenger
RNA, peptides, proteins, or metabolites resulting in patterns
(or ‘signatures’) as biomarkers. Biomarkers have relevance to
medical practitioners and other healthcare professionals,
researchers, the general public, patient subgroups, industry,
healthcare funders, regulators and policy makers. It is important
to distinguish between biomarkers, risk factors and endpoints.
Biomarkers are biological characteristics that are measured and
evaluated. As a consequence, they are subject to measurement
quality issues such as accuracy, precision, reliability, reproduci-
bility, and the need for standards and quality control. Risk factors
are variables that are related to an increased probability of
developing a disease or injury; they may include biomarkers but
also social and environmental factors. Endpoints are clinical
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outcomes or events. Surrogate biomarkers are substitutes for
clinically meaningful endpoints and are expected to predict the
effect of a therapy(2), but not all biomarkers predict risk or function
as endpoints.
Biomarkers, risk factors and endpoints are all very relevant to
nutrition research and are widely used. However, nutrition
researchers are often interested in a broader range of exposures
and outcomes. These may include food, nutrient and non-nutrient
intake from the diet; behaviour in the context of food or nutrient
exposure; psychological as well as physiological outcomes; and
well-being. Fig. 1 depicts the relationship between dietary
exposure, nutrient status, and the impact of nutrition on growth,
development, behaviour, and psychological and physiological
function, which in turn inﬂuence health, wellbeing and disease
risk. A concept that deﬁnes biomarkers, bio-indicators and public
health indicators as types of measures in nutritional assessment
has recently been introduced(3). Hence, the term ‘markers’ is used
herein to distinguish this broader range of nutritional interests
from the narrower focus upon physiological ‘biomarkers’ (Fig. 1);
note that ‘markers’ will include ‘biomarkers’.
The conduct of high-quality nutrition research requires the
selection of appropriate markers as outcomes, for example as
indicators of food or nutrient intake, nutritional status, health
status or disease risk. The selection of suitable markers will allow
a research question to be robustly addressed, but such selection
requires detailed knowledge of the markers, and consideration of
the factors that may inﬂuence the measurement of these markers,
other than the effects of nutritional change. A framework to
guide selection of markers within nutrition research studies would
be a valuable tool for researchers in the ﬁeld. In this context, a
key conclusion of the European Commission-funded project
PASSCLAIM (Process for the Assessment of Scientiﬁc Support for
Claims on Foods), coordinated by the European Branch of the
International Life Sciences Institute (ILSI Europe), was that there is
a lack of adequate markers in nutrition sciences and that there is a
high need for such markers(4). ILSI Europe therefore launched an
activity, ‘Marker Initiative on Nutrition Research’, with the aim
of identifying and reviewing criteria for validation of markers.
It was envisaged that this would be a multi-step process, as
illustrated in Fig. 2. The ﬁrst step was the identiﬁcation of those
criteria that have been used to assess a broad range of markers in
nutrition research. This was followed by a Workshop, ‘Obtaining
consensus on the criteria for evaluating markers in nutrition
research’, held in June 2012 in Lisbon, Portugal, comprising step 2
of the process (see Fig. 2). During the Workshop, participants
established a preliminary list of consensus criteria for marker
evaluation for nutrition research(5):
(1) The marker should be validated according to recognised
methods;
(2) The marker should reﬂect an endpoint (there should
be a signiﬁcant association between the marker and an
endpoint in a target population and the marker should
change consistently with a change in the endpoint);
(3) The marker must respond to a dietary intervention.
The next step in the process (step 3), the current activity, was to
assess the use of these criteria, using a range of different pos-
sible markers reﬂecting the breadth of nutrition research pos-
sibilities in order to test whether the criteria were ﬁt for purpose,
and, if not, to propose alternatives. The current activity was
performed by a multi-disciplinary Expert Group, members of
which discussed all aspects under consideration until
consensus was reached. This article conveys the result of those
discussions. One outcome of the current activity is a revised list
of criteria, incorporated into a template. A second role of the
current activity was to consider the development of methods
for scoring markers against the pre-speciﬁed criteria, and to
develop a template for this purpose. Review of ‘nutritional
(bio)markers’ themselves was outside the remit of the Expert
Group, the overall aim of which was to (re)consider the process
by which such markers can be evaluated.
Testing the proposed criteria
It was considered that the best way to test the criteria was to
complete a template based on the criteria established by de Vries
et al.(5) (see Table 1) using examples of markers that reﬂect:
(1) A broad range of interests in nutrition research (see Fig. 1);
(2) The use of different tools, including both questionnaires
and laboratory tests;
(3) Both long-established and newer markers and tools;
(4) Commonly used and not commonly used markers.
Hence, the markers selected are not necessarily well validated or
widely accepted. Markers covering the ﬁelds of nutrient intake,
nutrient status, physiological function, metabolism, cognitive
function and disease risk were all evaluated (Table 2).
Individual members of the multidisciplinary Expert Group
completed the draft template (Table 1) using the criteria
proposed in step 2 (de Vries et al.(5)) (henceforth ‘proposed
criteria’, see Fig. 2) for each of the markers selected and then the
completed template was discussed amongst all members and
modiﬁcations made until consensus on the utility of the criteria for
each marker was reached. One completed template is included
(Table 3), while the completed templates for each of the thirteen
markers are included in the online Supplementary material.
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Fig. 1. Contexts of markers in nutrition research. There is a relationship between
dietary exposure, nutrient status, and the impact of nutrition on growth,
development, behaviour, and psychological and physiological function, which in
turn influence health, wellbeing and disease risk. Nutrition research requires
validated markers for each of these levels. Note that the same measure may
serve as both a marker and an outcome, depending upon the context.
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Reﬁning the criteria and developing a new evaluation
template
As experts evaluated the proposed criteria and during the
subsequent discussions, a number of pertinent points emerged
regarding the ease of use, utility and relevance of the criteria
and also the exact wording used to describe/deﬁne criteria.
Although several of the core components that form part of the
criteria are clearly deﬁned (for example, sensitivity, speciﬁcity),
others are not (for example, robustness), making it difﬁcult to
address these less well-deﬁned criteria. Furthermore, in the
absence of clear deﬁnitions, different individuals interpret the
meaning of these terms or criteria differently, resulting in a less
robust and less reproducible (from individual to individual)
evaluation. It was recognised that, despite that fact that some
markers are widely used, they fail to meet some of the criteria;
for example in some cases assays may be poorly standardised.
Furthermore, some measures are often used as endpoints
themselves rather than as markers of other endpoints (out-
comes); for example verbal memory, a marker of cognitive
function, is often reported as an endpoint in its own right. Also,
some markers have remained in use over a very long period of
time, perhaps because they become validated or well accepted
or, in some cases, because they are easy to use. On the other
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Fig. 2. The International Life Sciences Institute (ILSI) Europe Marker Initiative on Nutrition Research: a stepwise approach towards criteria for the evaluation of
markers in different fields of nutrition research.
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hand, some markers cease to be used after a period of
time while new markers can emerge. Thus, there is a certain
level of ‘turnover’ of markers. This has been hastened by the
emergence of new technologies, typically ‘omics’-based, that
have enabled the simultaneous measurement of clusters or
patterns of markers. Some of these seem likely to replace
existing single-measurement markers, although validation of the
patterns, access to the technology and cost remain barriers. An
example of how the marker ﬁeld is developing is the proposal
of a composite biomarker called the ‘vascular health index’
based on the integration of a meticulously selected cluster
of biomarkers all related to vascular health measured with
different types of analytical techniques(6).
Many markers are evaluated in a static setting, for example
in fasting blood samples. This separates the sample and its
component markers from the reality of human physiology, which
is the need to respond appropriately to ‘daily stressors’ which
may be metabolic, immune, physical (for example, exercise,
temperature) or psychological. Thus, it may be desirable to
include a challenge test in a study protocol and to evaluate the
dynamic change in the marker in response to the challenge.
Some of the examples of markers used to test the criteria do
include a challenge test (for example, response to vaccination);
again it seems that in the future more studies will incorporate
challenge models to simulate events which could occur in the
natural environment(7,8). One area where challenge models have
become widely used in recent years in order to study the
dynamic change in a marker is the evaluation of inﬂammation.
For example, both high-fat and high-carbohydrate meals induce
an acute elevation in a number of biomarkers of inﬂammation(9)
and such challenges have been used to assess the effect of
including ﬁbre(9) or vitamin C(10) in the meal on the acute
inﬂammatory response that is elicited. Exposure of the skin to UV
irradiation induces inﬂammation and controlled exposures have
been used to assess the effects of including n-3 fatty acids(11) or
green tea catechins(12) in the diet on a range of biomarkers of
inﬂammation. Intramuscular injection of bacterial endotoxin
has been used to assess the effect of dietary n-3 fatty acids on
inﬂammation(13).
It also emerged that a marker may not be equally useful
across different applications. For example, a marker that is
informative in the controlled setting of a small intervention
study may be much less informative, or even unfeasible, in the
setting of a large observational study.
The proposed criteria included ‘Must respond to a dietary
intervention’. However, upon further discussion it was
considered that whether a measure (i.e. a marker) is sensitive to
nutrition does not make it a better or worse marker. This will
depend on what the marker is designed to measure. Further,
when considering whether a marker is inﬂuenced by a dietary or
other intervention, then the extent of the effect seen (or foreseen)
needs to be taken into account. This poses a challenge because
studies are typically powered to show a statistically signiﬁcant
change in the marker being used. Even if that marker has an
association with an endpoint, a statistically signiﬁcant change in
the marker may not be of clinical signiﬁcance or even biological
signiﬁcance. Conversely, a change that is clinically signiﬁcant
may not be statistically signiﬁcant in a study setting. Thus, it
would seem prudent when planning a nutrition study to consider
both clinical and statistical signiﬁcance of the change being
sought. Such considerations of study design, including effect size,
are discussed elsewhere(14). It was concluded that the two criteria
listed in the section ‘Reﬂect/mark an endpoint’ were essentially
addressing the same point: that a relationship exists between the
marker and an endpoint of interest. It was difﬁcult for experts to
adequately complete the section on ‘Analytical aspects’ because
the different criteria asked about in this section were not well
separated. Thus, by completing the draft template, based upon
the proposed criteria, a number of the components of the
proposed criteria were identiﬁed for change or improvement.
It was also identiﬁed that providing information on normal values
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Table 2. Markers used to assess the proposed criteria according to their
specific field of application
Specific field of application Marker
Nutritional epidemiology Vitamin C intake determined by FFQ
Nutritional epidemiology Serum/plasma vitamin B12 as a status
marker
Immune function Response to vaccination
Cognitive function Verbal memory
Cognitive function Sustained attention
CVD/chronic inflammation C-reactive protein concentration in
plasma/serum
CVD/vascular function Flow-mediated dilation
CVD/oxidative stress F2-isoprostane concentrations in urine
CVD – blood pressure Blood pressure
Metabolism and metabolic
dysfunction
Branched-chain amino acids and their
derivatives in plasma
Metabolism and metabolic
dysfunction
FADS1 genetic polymorphisms
Intestinal barrier function/
intestinal permeability
Lactulose:mannitol ratio in urine
Energetics/obesity Energy expenditure measured by doubly
labelled water
FADS1, fatty acid desaturase 1.
Table 1. Template to aid the evaluation of candidate markers for their
usefulness in nutrition research according to previous step 2 of the Marker
Initiative on Nutrition Research (de Vries et al. (2013)(5))
Criteria identified at the workshop Comments
1. Analytical aspects
(i) Method should be validated according to recognised
guidelines
(ii) This should include for example: robustness,
appropriate analytical sensitivity and specificity,
reproducibility accuracy, quality assurance,
standardisation, traceability, stability (quality of the
sample). These guidelines can be specific per marker;
they apply equally well to biological markers, imaging,
questionnaires, etc.
2. Reflect/mark an endpoint
(i) Significant association between marker and endpoint in
a target population
(ii) Marker changes consistently with a change in the
endpoint
3. Must respond to a dietary intervention
(i) Any dietary intervention should induce a meaningful
change in the marker (meaningful refers to 2 (ii))
(ii) Lifestyle changes (which may include changes in the
diet) may also induce a meaningful (meaningful refers to
2 (ii)) change in the marker
4 P. C. Calder et al.
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Table 3. Example of a completed template: use of response to vaccination as a marker of immune competence
Criteria to evaluate markers Comments
1. Analytical aspects
(i) Method should be validated according to recognised
guidelines
(ii) This should include for example: robustness, appropriate
analytical sensitivity and specificity, reproducibility,
accuracy, quality assurance, standardisation, traceability,
stability (quality of the sample), analytical variation,
biological variation (these guidelines can be specific per
marker; they apply equally well to biological markers,
imaging, questionnaires, etc.)
Vaccination is a means of exposing the immune system to one or more antigens in a standardised and controlled manner. In response to
vaccination, the host mounts an immune reaction that culminates in the production of anti-vaccine antibodies. The use of vaccination in an
experimental setting (for example, in a study of a nutritional intervention) involves vaccinating a participant (usually intramuscularly) with a
commercial clinically used vaccine (for example, influenza, tetanus, pneumococcus,) and obtaining blood samples at specific time points
thereafter. Anti-vaccine antibodies are measured in serum or plasma prepared from the blood. The serum/plasma needs to be stored frozen
(–80°C) until antibodies are measured. Accredited laboratories can be used to measure responses to some vaccines (for example, WHO-
accredited laboratories for anti-influenza vaccine antibodies). Such laboratories use validated methodology that is recognised by the WHO and
other authorities. This may not be the case for all anti-vaccine antibody measurements. Where there is an accredited laboratory many of the
analytical aspects are of the highest quality. For some vaccines there are definitions of seroprotection and seroconversion, although these
definitions can differ between countries. Seroprotection means that the individual has a high probability of being protected and it is defined as
having an antibody titre (level) above a particular threshold. For seasonal influenza vaccination, seroprotection is defined as having an antibody
level of 40 haemagglutination inhibition units/ml or higher, while for diphtheria and tetanus it is defined as having an antibody level of 0·1 IU/ml or
higher. Seroconversion is commonly defined as having at least a 4-fold increase in antibody levels following vaccination. Discussions of the
relationship between seroprotection, seroconversion and clinical protection may be found in the literature. Note that an individual can show
seroconversion but still not be seroprotected and that, conversely, reaching the threshold for seroprotection may require less than a 4-fold
increase in antibody levels (i.e. may not require seroconversion). Within a population there is substantial variation in the antibody response to
many vaccines. The tables below show unpublished results (AL Lomax and PC Calder) from a study of forty-three healthy human subjects aged
40–65 years vaccinated with the 2008/2009 seasonal influenza vaccine. The data are based upon serum antibody titres 4 weeks post-
vaccination. The seasonal influenza vaccine contains subunits of three different viral strains so that three separate antibody responses are
measured.
Percentage of subjects who seroconverted and became seroprotected from a study of forty-three healthy human subjects aged 40–65 years
vaccinated with the 2008/2009 seasonal influenza vaccine (unpublished results)
% of subjects
who
% of subjects
who became
Antibody titre (haemagglutination inhibition units/ml)
Viral antigen
type seroconverted seroprotected Lowest Median Highest
HAH1 79·1 72·1 5 80 15360
HAH3 79·1 81·4 5 320 20480
HAB 59·1 60·4 5 60 960
% who seroprotected % who seroconverted
To none of
the viral
antigens
To only one of
the viral
antigens
To any two of
the viral
antigens
To all three of
the viral
antigens
To none of the
viral antigens
To only one of
the viral
antigens
To any two of
the viral
antigens
To all three of
the viral
antigens
4·7 18·6 34·9 41·9 2·3 20·9 34·8 41·9
These data show large variations in antibody response between individuals (i.e. within a population) and also that there is variation in
response to several antigens administered together within an individual. The ability of vaccinations to initiate a robust host immune
response, and so to produce clinical protection, is recognised to be poorer in the elderly (see below), the frail, the malnourished and
those with certain chronic diseases. For clinical protection against some diseases the same vaccine can be used unchanged over many
years. However, because of the rapid mutation rate of seasonal influenza viruses, the exact make-up of the seasonal influenza vaccine
changes from year to year. The three strains that have been used in the vaccine over the years may be found on many websites (for
example, http://www.who.int/influenza/vaccines/virus/recommendations/en/). Some vaccinations (for example, polio) give life-long
protection; others (for example, tetanus) give shorter protection.
For a primary antibody response, the subject cannot have received the same vaccine previously. Administration of a vaccine to an individual who
has received it already can induce a secondary antibody response, which may be different in kinetics and vigour from the primary response.
Responses to vaccination may be modified by many factors including age and health status. For example, the success of the seasonal influenza
vaccine is much less in individuals aged over 65 years than in middle-aged adults. Goodwin et al. (2006)(17) noted that in young healthy adults
the seasonal influenza vaccine provides a protective clinical efficacy in 70 to 90% of cases, which is reduced to only 17 to 53% in elderly
individuals. This reflects a general decline in cell-mediated immunity that occurs, to varying extents, with ageing; this is termed
immunosenescence(18,19)
ILSI
E
u
ro
p
e
M
arker
In
itiative
fo
llo
w
-u
p
5
https://doi.org/10.1017/S0954422416000263
D
ow
nloaded from
 https:/w
w
w
.cam
bridge.org/core. U
niversity of Leeds, on 16 M
ar 2017 at 11:18:54, subject to the C
am
bridge C
ore term
s of use, available at https:/w
w
w
.cam
bridge.org/core/term
s.
Nutrition Research Reviews
Table 3. Continued
Criteria to evaluate markers Comments
2. Reflect/mark an endpoint
(i) Significant association between marker and endpoint
in a target population
(ii) Marker changes consistently with a change in the
endpoint
The production of antibodies in response to vaccination represents an integrated read-out of the immune response – it will have required
the activity of antigen-processing and -presenting cells, T cells and B cells. It is considered to be superior to any individual laboratory-
based immune marker(15,16) and is one of the few immune biomarkers considered to be of high value in human nutrition studies.
Response to vaccination can be defined by seroprotection and seroconversion (described in the previous section) and is considered to be
related to clinical outcome (i.e. protection from the infective agent), although this can be poorly defined. For the seasonal influenza
vaccination seroprotection and seroconversion thresholds are defined by the WHO (see the previous section) – in clinical practice these
are often not met (for example, in the elderly) but neither the clinician nor the patient is aware of this. Such a failure may allow
susceptibility to the infectious agent, so in this sense a poor response can increase risk of poor clinical outcome (i.e. infection and
its severity) while a good response can decrease risk of poor clinical outcome (i.e. infection and its severity)
3. Must respond to a dietary intervention
(i) Any dietary intervention should induce a meaningful
change in the marker (meaningful refers to 2 (ii))
(ii) Lifestyle changes (which may include changes in the diet)
may also include a meaningful (meaningful refers to 2 (ii))
change in the marker
Response to vaccination may be used in epidemiology studies to investigate the association between the immune response and a future
clinical outcome (prospective study) or between the intake of foods or nutrients and the immune response (cross-sectional study) or in
intervention trials of dietary or nutrient modifications. The response to vaccination, based upon antibody titres measured at an
appropriate time point after vaccination, may be represented in several different ways: antibody titre concentrations; change in antibody
titre concentrations from the pre-vaccinated state; fold-change in antibody titre concentrations from the pre-vaccinated state; % of
individuals seroprotected; % of individuals seroconverted; % of individuals seroconverted and seroprotected (see the previous section).
Each of these may be a valid marker of immune response, although the clinical meaning of the outcomes may be different. For example,
in a controlled trial it is possible that no subjects seroconvert or become seroprotected but that there is still a statistically significant effect
of an intervention on antibody titres compared with a control group. Conversely, it is possible that all subjects in a study seroconvert and
become seroprotected but that there is still a statistically significant effect of an intervention on antibody titres compared with a control
group. In both of these scenarios it might be interpreted that there is an improvement in immune response, although the clinical meaning
of this improvement may be different.
Some studies have shown improved response to vaccination with a dietary intervention, while others have not. Studies involving prebiotics
and response to vaccination were included in the review by Lomax & Calder (2009)(20), while studies of probiotics were reviewed by
Lomax &Calder (2009)(21) and by Maidens et al. (2013)(22). Examples of studies where improvements in response to seasonal influenza
vaccination have been demonstrated include Boge et al. (2009)(23), Langkamp-Henken et al. (2006)(24) and Langkamp-Henken et al.
(2004)(25).
Boge et al. (2009)(23) reported two controlled studies of oral Lactobacillus casei DN-114 001 administration for 7 weeks (study 1) and
13 weeks (study 2) in elderly subjects (>70 years of age; mean age about 84 years) who received the seasonal influenza vaccine after
4 weeks. Study 1 used the 2005/2006 seasonal influenza vaccine and identified 40 to 50% seroprotection and 20–50% seroconversion
(depending upon viral strain) in the control group 3 weeks post-vaccination, in keeping with the relatively poor response to vaccination in
the elderly. This study, which involved approximately forty subjects per group (i.e. control and L. casei), showed non-significant trends
towards higher antibody titres and increased seroprotection and seroconversion with L. casei. Study 2 was larger (about 110 subjects in
each group) and measured antibody titres 3, 6 and 9 weeks post-vaccination with the 2006/2007 vaccine. The study revealed higher
antibody titres to all three vaccine strains at all three post-vaccination time points, although these were significant only for antibodies
against the B strain (at all three time points); typically antibody titres were 60 haemagglutination inhibition units/ml in the control group
and 100 in the L. casei group. Seroconversion to the B strain was low in the control group (about 10% at 3 weeks) but was significantly
increased by L. casei at all times points assessed (about 20% at 3 weeks). Seroconversion at 5 months post-vaccination was higher to
the B strain (about 7% v. about 2%) and to the H3N2 strain (about 20% v. about 10%) with L. casei.
Langkamp-Henken et al. (2004)(25) reported a controlled study of 26 weeks administration of an oral nutritional formula providing vitamins E and C,
β-carotene, B vitamins, Se, Zn, structured TAG and the prebiotic fructo-oligosaccharide. Subjects were older adults (>65 years; mean age
about 82 years) who received the 1999/2000 seasonal influenza vaccine after 2 weeks. Antibody titres to the H3N2 and B strains were not
different between groups at 6 weeks or 24 weeks post-vaccination. In contrast, 6 weeks post-vaccination antibody titres to the H1N1 strain
were significantly higher in the formula group (about 200 v. about 100). Seroprotection to each of the three viral strains was not different
between groups at 6 weeks post-vaccination. Seroconversion to the H1N1 strain was higher in the formula group (87% v. 41%) but there was
no difference between groups in seroconversion to the H3N2 or B strains. In the formula group 87% of subjects seroconverted and
seroprotected to the H1N1 strain which was significantly higher than in the control group (35%). This study also reported cold and influenza
symptoms over the study period: days with symptoms per subject were lower in the formula group (median 0 v. 3).
Langkamp-Henken et al. (2006)(24) reported a controlled study of 10 weeks administration of the same oral nutritional formula in older adults (>65
years; mean age about 85 years) who received the 2002/2003 seasonal influenza vaccine after 4 weeks. The study identified about 45%
seroconversion to the H1N1 strain and about 35% to the H3N2 strain with no effect of the nutritional formula. Seroconversion to the B strain
was about 50% in the control group and 64% in the formula group (P=0·09). Seroprotection to the H1N1 strain was higher in the formula
group (44 v. 29%), and tended to be higher to the H3N2 strain (97% v. 89%) but wasn’t different to the B strain (95 v. 94%). Antibody titres to
any strain were not different between groups
Conclusions Response to vaccination, assessed as anti-vaccine antibodies in serum or plasma, can be used as a biomarker of immune function in both
epidemiological and intervention studies. However, there is high variability in response between subjects
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or ranges in different population subgroups and thresholds used
to make different conclusions would be very valuable and was
not explicitly requested in the draft template. It was also felt that
sections in a new template to add other relevant information, for
example to record inconsistencies in the literature, to make a
clear conclusion about the usefulness of the marker under
consideration, including any important limitations, and to record
references used would all be valuable.
The above considerations led the Expert Group to conclude
that the proposed criteria could be improved upon and therefore
the draft template (Table 1) was revised to produce a new
template reﬂecting these improvements (Table 4). This retains the
general features of the proposed criteria (as described in the draft
template), but the template is formatted in a way that is easy for
the end-user to complete with a clearer indication of the nature of
the information that is required for each section. The section
‘Methodological aspects’ (previously termed ‘Analytical aspects’)
explicitly separates the most important components (validation;
sensitivity; speciﬁcity; technical aspects other than sensitivity and
speciﬁcity; biological variation), providing an opportunity to
consider these individually. The section ‘Reﬂects the biological
purpose of the marker’ (previously ‘Reﬂects/marks an endpoint’)
combines the two previous criteria (‘Signiﬁcant association
between marker and endpoint in a target population’ and ‘Marker
changes consistently with a change in the endpoint’) into a single
reworded criterion (‘A change in the marker is linked with a
change in the endpoint in one or more target population(s)’). This
is because the two previous criteria address the same point, both
stating that a relationship exists between the marker and an
endpoint of interest. The section ‘Relevance to nutrition research’
(previously termed ‘Must respond to a dietary intervention’)
expands upon and presents a change in focus from the proposed
criteria. Now information on the normal range of values can be
entered and the requirement that the marker must respond to a
dietary intervention is replaced by a question seeking the
evidence that nutrition can inﬂuence the marker and, if so, the
extent of the reported effect. The reason for this change in focus is
that whether a measure is sensitive to nutrition or not does not
make it a better or worse marker, although it may make it more or
less attractive to researchers and other stakeholders. Finally, in
this section a question about other factors that might affect the
marker is now included. A section ‘Other relevant information’ is
included and there are cells for ‘Conclusion’ and to record
‘References’. It is considered that these changes will make the
criteria and associated template more useful and more robust.
It is anticipated that once a particular marker has been assessed
using the criteria and the associated template, the information will
be used as the basis for scoring the marker in order to determine
its usefulness as a research tool. Such scoring requires a suitable
methodological approach (see next paragraph).
Towards developing a marker scoring system
Examples of scoring systems may be found in Albers et al.(15,16)
where markers of immune function were evaluated by scoring
them against a range of predetermined criteria; in Albers et al.(16)
these related to clinical relevance, biological sensitivity and
feasibility. Table 5 is the generic marker scoring template
now proposed. Researchers would score any marker under
consideration according to the different criteria listed in the
upper section of Table 4 as proven (+++ ), strong ( ++ ), medium
( + ) or low (0). Additionally, an arbitrary marker score would be
based on subjective expert judgement on the usefulness of a
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Table 4. Refined template to aid the evaluation of candidate markers for their usefulness in nutrition research
Criteria to evaluate markers Comments
Specific field and related marker
SCORING CRITERIA
Methodological aspects excluding study design
(Relevance of criteria can differ between different types and applications of markers)
Method should be validated according to recognised guidelines (please cite)
Appropriate* sensitivity
Appropriate* specificity
Reproducibility, accuracy, standardisation, stability (quality of the sample) and technical variation
Biological variation
Reflect/mark the study objective
A change in the marker is linked with a change in the endpoint in one or more target population(s)
Method should be validated according to recognised guidelines (please cite)
ADDITIONAL INFORMATION
Relevance to nutrition research
What is considered as a normal range for healthy people?
What is a significant change (consider both biological and statistical)?
(might vary for different applications, e.g. epidemiological studies v. individual level)
Is there evidence that nutrition influences the marker? If so, what is the size of the effect reported?
Which other factors also have an effect on the marker? (if any)
Other relevant information
Are there experimental data where dietary intervention has not resulted in an anticipated change?
Conclusions
References
* Appropriate is used here to indicate that the required sensitivity and specificity of measurement may differ between study contexts, for example between a large epidemiological
study and a much smaller randomised controlled trial.
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marker based on carefully considered evaluation of individual
criteria. This would enable researchers to evaluate and to
compare different candidate markers within the same ﬁeld of
nutrition research in order to identify their relative usefulness.
The criteria for a ranking of proven, strong, medium or low are
likely to vary according to the research setting (for example,
epidemiology, intervention, mechanistic investigation), the
research ﬁeld (for example, immune function, cognitive function,
metabolism and metabolic dysfunction), and the type of tool
used to assess the marker and therefore the ranking criteria need
to be determined in a setting-, ﬁeld- and tool-speciﬁc manner.
Examples of such criteria and their use in evaluating immune
markers may be found in Albers et al.(16). It is expected that
researchers would develop scoring deﬁnitions and then score
and rank potential markers as part of study planning.
Summary and conclusions
An Expert Group set out to test proposed criteria (see Table 1)
designed to aid the evaluation of candidate markers for their
usefulness in nutrition research and subsequently to develop a
scoring system for markers. The criteria were tested using a total
of thirteen markers selected from a breadth of ﬁelds of nutrition
research (Table 3 and online Supplementary material). The
result of this testing was a modiﬁed list of criteria and a template
(see Table 4). It is considered that these changes will make
marker assessment easier and more robust. Subsequently a
system for scoring a marker and an associated template were
developed (Table 5). This system would enable researchers to
evaluate and to compare different candidate markers within the
same ﬁeld of nutrition research in order to identify their relative
usefulness. The ranking criteria of proven, strong, medium or
low are likely to vary according to research setting, research
ﬁeld and the type of tool used to assess the marker and
therefore the criteria need to be determined in a setting-, ﬁeld-
and tool-speciﬁc manner. Examples of such ranking criteria for
immune function markers may be found in Albers et al.(16). It is
anticipated that deﬁning the scoring system and then using this
to score possible markers would be done by researchers as a
part of their study planning. These activities and the develop-
ment of the templates described in Tables 4 and 5 complete
step 3 of ILSI Europe’s marker initiative programme (see Fig. 2).
The next step is to use the evaluation criteria and scoring system
to evaluate markers. It is anticipated that ILSI Europe will hold
an open access ‘library’ of completed evaluations, using the
templates developed in this activity that will be available to
the nutrition community for use, comment, modiﬁcation and
updating. Besides applying the evaluation tool in study
planning, researchers would complete templates with scenarios
of marker applications to populate such a library with evaluated
markers from various ﬁelds of nutrition research. It is important
to note that many of the markers considered here and in the
future are of interest to research communities beyond the ﬁeld
of nutrition and, as such, the library of ILSI Europe marker
evaluations will be a valuable resource for a wide research
community and for other relevant stakeholders (for example,
industry, regulators, medical practitioners).
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